These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 15117932)
1. Antibiotic treatment of gram-positive bone and joint infections. Darley ES; MacGowan AP J Antimicrob Chemother; 2004 Jun; 53(6):928-35. PubMed ID: 15117932 [TBL] [Abstract][Full Text] [Related]
2. [Linezolid in the treatment of antibiotic-resistant gram-positive infections of the musculoskeletal system]. Jahoda D; Nyc O; Pokorný D; Landor I; Sosna A Acta Chir Orthop Traumatol Cech; 2006 Oct; 73(5):329-33. PubMed ID: 17140514 [TBL] [Abstract][Full Text] [Related]
3. Role of linezolid in the treatment of orthopedic infections. Bassetti M; Righi E; Di Biagio A; Rosso R; Beltrame A; Bassetti D Expert Rev Anti Infect Ther; 2005 Jun; 3(3):343-52. PubMed ID: 15954851 [TBL] [Abstract][Full Text] [Related]
4. [Linezolid--novel antibiotic for the treatment of gram-positive bacterial infections]. Jankowski A; Stefanik W Wiad Lek; 2006; 59(9-10):727-31. PubMed ID: 17338140 [TBL] [Abstract][Full Text] [Related]
5. Linezolid in the treatment of Gram-positive prosthetic joint infections. Bassetti M; Vitale F; Melica G; Righi E; Di Biagio A; Molfetta L; Pipino F; Cruciani M; Bassetti D J Antimicrob Chemother; 2005 Mar; 55(3):387-90. PubMed ID: 15705640 [TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center. Smith PF; Booker BM; Ogundele AB; Kelchin P Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606 [TBL] [Abstract][Full Text] [Related]
7. Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections. Kanafani ZA; Corey GR Expert Rev Anti Infect Ther; 2007 Apr; 5(2):177-84. PubMed ID: 17402833 [TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria. Rybak MJ Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():24-32. PubMed ID: 16445721 [TBL] [Abstract][Full Text] [Related]
9. Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureus. Wang JL; Tang HJ; Hsieh PH; Chiu FY; Chen YH; Chang MC; Huang CT; Liu CP; Lau YJ; Hwang KP; Ko WC; Wang CT; Liu CY; Liu CL; Hsueh PR Int J Antimicrob Agents; 2012 Aug; 40(2):103-7. PubMed ID: 22612900 [TBL] [Abstract][Full Text] [Related]
11. [Peptostreptococcus magnus osteoarticular infections after orthopedic surgery. 14 cases and pathogenicity factors]. Felten A; Desplaces N; Nizard R; Sedel L; Lagrange P Pathol Biol (Paris); 1998 Jun; 46(6):442-8. PubMed ID: 9769879 [TBL] [Abstract][Full Text] [Related]
12. [Osteoarticular infections: therapeutic proposals of the Paediatric Infectious Diseases Group of the French Society of Paediatrics (GPIP)]. Grimprel E; Lorrot M; Haas H; Pinquier D; Parez N; Ferroni A; Cohen R; Arch Pediatr; 2008 Oct; 15 Suppl 2():S74-80. PubMed ID: 19000859 [TBL] [Abstract][Full Text] [Related]
13. Daptomycin in bone and joint infections: a review of the literature. Rice DA; Mendez-Vigo L Arch Orthop Trauma Surg; 2009 Nov; 129(11):1495-504. PubMed ID: 18989686 [TBL] [Abstract][Full Text] [Related]
14. Bacterial incidence and antibiotic sensitivity pattern in moderate and severe infections in hospitalised patients. Ghosh A; Karmakar PS; Pal J; Chakraborty N; Debnath NB; Mukherjee JD J Indian Med Assoc; 2009 Jan; 107(1):21-2, 24-5. PubMed ID: 19588683 [TBL] [Abstract][Full Text] [Related]
15. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia. Erlandson KM; Sun J; Iwen PC; Rupp ME Clin Infect Dis; 2008 Jan; 46(1):30-6. PubMed ID: 18171210 [TBL] [Abstract][Full Text] [Related]
16. Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens. Das B; Sarkar C; Biswas R; Pandey S Pak J Pharm Sci; 2008 Jan; 21(1):78-87. PubMed ID: 18166524 [TBL] [Abstract][Full Text] [Related]
17. New antibiotic agents for bloodstream infections. Vergidis PI; Falagas ME Int J Antimicrob Agents; 2008 Nov; 32 Suppl 1():S60-5. PubMed ID: 18723329 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. Florescu I; Beuran M; Dimov R; Razbadauskas A; Bochan M; Fichev G; Dukart G; Babinchak T; Cooper CA; Ellis-Grosse EJ; Dartois N; Gandjini H; J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i17-28. PubMed ID: 18684703 [TBL] [Abstract][Full Text] [Related]
19. Place of newer quinolones and rifampicin in the treatment of Gram-positive bone and joint infections. Frippiat F; Meunier F; Derue G J Antimicrob Chemother; 2004 Dec; 54(6):1158; author reply 1159. PubMed ID: 15498877 [No Abstract] [Full Text] [Related]
20. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms. Garrison MW; Neumiller JJ; Setter SM Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]